Orthopoxvirus mature virion and extracellular enveloped virion surface antigen (OPXV MV/EEV antigen)

Orthopoxvirus mature virion (MV) and extracellular enveloped virion (EEV) surface antigens are critical components of the viral life cycle for pathogens such as Variola virus and Monkeypox virus (Source: NIH, PMC7113668). The MV is the most abundant infectious form, primarily responsible for transmission between hosts, while the EEV is specialized for efficient long-range dissemination within the host's body (Source: Nature Reviews Microbiology, 2004). These surface antigens, including proteins like L1, A27, A33, and B5, facilitate host cell attachment, membrane fusion, and protection against the host's immune system (Source: Journal of Virology, 2012). Therapeutic strategies often target these antigens to neutralize the virus or disrupt its assembly and release. For instance, the antiviral drug Tecovirimat specifically inhibits the F13 protein (VP37), which is essential for wrapping the MV to form the EEV, effectively halting the spread of the infection (Source: FDA, TPOXX Label). Vaccines like JYNNEOS and ACAM2000 also utilize these antigens to prime the immune system, generating neutralizing antibodies that recognize and bind to the virion surface to prevent infection (Source: CDC, 2023).

Other names

Orthopoxvirus surface proteinPoxvirus envelope antigenMV and EEV proteinOrthopoxvirus membrane protein

Tecovirimat inhibits the orthopoxvirus VP37 envelope wrapper protein (encoded by the F13L gene), which is required for the production of extracellular enveloped virions (EEV), thereby preventing viral egress and spread (Source: FDA). Vaccinia Immune Globulin and vaccine-induced antibodies bind directly to mature virion (MV) and EEV surface antigens (such as L1, A27, A33, and B5) to neutralize the virus and prevent host cell entry (Source: CDC, NIH).